Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
AssigneeTakeda Pharmaceutical Company Limited
InventorsMiranda Chapman, Bruce Ewenstein, Bettina Ploder
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
Claims20
A method for treating mild or moderate gastrointestinal bleeding in a subject with severe von Willebrand Disease (VWD) comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) each ranging from about 40 IU/kg to about 60 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII) ranging from about 20 to about 50 IU/kg.
A method for treating major or severe gastrointestinal bleeding in a subject with severe von Willebrand Disease (VWD) comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) each ranging from up to about 80 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII) ranging from about 20 to about 40 IU/kg.
Dependencies are inferred from the claim text.